Market Overview

Goldman Sachs Sees 100% Upside In This Biopharma Company

Share:
Goldman Sachs Sees 100% Upside In This Biopharma Company
Related RVNC
50 Biggest Movers From Yesterday
JMP: Changing Competitive Landscape Makes Revance Less Appealing

Revance Therapeutics Inc (NASDAQ: RVNC) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate.

The Rating

Goldman Sachs analysts Dana Flanders and Christopher Staral initiated coverage on Revance with a Buy rating and a $60 price target.

The Thesis

Revance’s injectable DaxibotulinumtoxinA will soon penetrate and rise in a $3 billion global neuromodulator market expected to post 11-percent compound annual growth through 2023.

Goldman Sachs foresees long-term opportunity in the treatment of glabellar lines, cervical dystonia and plantar fasciitis — expectations supported by physician surveys indicating a potential premium to Botox pricing and few challenges from Allergan plc Ordinary Shares (NYSE: AGN)’s cosmetic portfolio.

The analysts forecast peak sales north of $1.1 billion, which may secure Revance looks from outside parties.

“Given the attractiveness of the global neuromodulator market […] and growth potential from label expansion opportunities for Daxi, we also see high likelihood of M&A interest in RVNC over time,” Flanders and Staral wrote in a note.

Risks to their thesis include slow commercial uptake, competition and regulatory roadblocks.

Price Action

Shares spiked 5.4 percent on the coverage initiation. At time of publication, Revance's stock traded up 1.9 percent off Monday's open at $31.90.

Related Links:

Botox Competition Spurs Argus To Downgrade Allergan

The Companies That Led 2017's Biotech Rally

Latest Ratings for RVNC

DateFirmActionFromTo
Sep 2018JMP SecuritiesDowngradesMarket OutperformMarket Perform
Mar 2018Goldman SachsInitiates Coverage OnBuy
Jan 2018GuggenheimDowngradesBuyNeutral

View More Analyst Ratings for RVNC
View the Latest Analyst Ratings

Posted-In: Christopher Staral Dana Flanders DaxibotulinumtoxinAAnalyst Color Price Target Initiation Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (AGN + RVNC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Analysis: Negative Reaction To Trump's Tariffs Could Make Him More Likely To Act

MackeyRMS Manages Research For Hedge Funds Around The World